Bibliography
- LOTVALL J: Pharmacological similarities and differences between β2-agonists. Respir. Med. (2001) 95(Suppl.B):S7-S11.
- JACK D: Safety by design. Drug Saf. (1990) 5(Suppl.1):4-23.
- CAZZOLA M, MATERA MG, LÖTVALL J: Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs (2005) 14:775-783.
- BROWN AD, BRYANS JS, BUNNAGE ME et al.: Discovery of novel inhaled long acting β2 agonists for asthma and COPD. Poster presentation at 13th RSC-SCI Medicinal Chemistry Symposium, Cambridge, UK (4-7 September 2005).
- NORMAN P: Respiratory disease markets and opportunities. Clearview Ltd (May 2005).
Patents
- PFIZER, INC.: WO2004032921 (2004).
- PFIZER, INC.: EP01440966 (2004).
- PFIZER, INC.: EP01477167 (2004).
- PFIZER, INC.: US20040229904 (2004).
- PFIZER, INC.: WO2004108676 (2004).
- PFIZER, INC.: WO2004108675 (2004).
- PFIZER, INC.: EP01574501 (2005).
- PFIZER, INC.: US20050215590 (2005).
- PFIZER, INC.: US20050215542 (2005).
- PFIZER, INC.: WO2005090287 (2005).
- PFIZER, INC.: WO2005090288 (2005).
- PFIZER, INC.: WO2005092887 (2005).
- PFIZER, INC.: WO2005092860 (2005).
- PFIZER, INC.: WO2005092841 (2005).
Website
- http://www.gsk.com/financial/pp_pipeline_standard.htm GSK product pipeline.